Finance
Starbucks slides as Wall Street worries its run out of room to grow
-
Piper Jaffray cut it’s price target for Starbucks
to $53 from $60. -
The firm is worried US sales growth could be stalling,
and says the stock will remain range bound until trends
improve. -
Shares of Starbucks fell about 1.8% in trading
Wednesday following the downgrade. -
Follow Starbucks’ stock price in real-time
here.
Starbucks
slid 1.8% in trading Wednesday after Piper Jaffray cut its
recommendation to “neutral” from “overweight,” citing a slowdown
in US same-store sales.
“We believe the stock is range bound at best until U.S. trends
improve,” analyst Nicole Miller Regan wrote in a note sent out to
clients on Wednesday,
per CNBC. “Our perspective is that there are issues around
inconsistent results, credibility of guidance, and management
transitions.”
Piper’s new price target is $53 a share — down from $60 in June,
and $70 for the better part of 2017. Wall Street’s average target
if $58, according to Bloomberg data.
In its most recent earnings report in July, Starbucks
said
same-store sales around the world rose just 1%. China — where
the chain has been growing the quickest — saw sales slip to 2%.
“I want to be clear that we have 100 percent confidence in our
growth strategy and the sustainability of the leadership position
we have built in the market,” CEO Kevin Johnson told analysts on
a conference call following the report.
Still, Wall Street remains concerned.
“To sustain improvement in comps, Starbucks must
execute on its key digital initiatives to expand relationships
and drive transaction growth,” Fitch, one of the largest
financial rating agencies, said earlier this month.
Starbucks on Wednesday confirmed Business Insider’s previous
reporting that the
Pumpkin Spice Latte, a fall favorite, will return on August 28
this year — its earliest launch ever — perhaps in a bid to
increase check size and bring the same-store sales number back to
where Wall Street would like.
Starbucks shares are down 7.8% this year.
-
Business7 days ago
Xaira, an AI drug discovery startup, launches with a massive $1B, says it’s ‘ready’ to start developing drugs
-
Entertainment5 days ago
Summer Movie Preview: From ‘Alien’ and ‘Furiosa’ to ‘Deadpool and Wolverine’
-
Business6 days ago
Petlibro’s new smart refrigerated wet food feeder is what your cat deserves
-
Entertainment4 days ago
What’s on the far side of the moon? Not darkness.
-
Business5 days ago
How Rubrik’s IPO paid off big for Greylock VC Asheem Chandna
-
Business5 days ago
Thoma Bravo to take UK cybersecurity company Darktrace private in $5B deal
-
Business4 days ago
TikTok faces a ban in the US, Tesla profits drop and healthcare data leaks
-
Business6 days ago
Zomato’s quick commerce unit Blinkit eclipses core food business in value, says Goldman Sachs